SGA disclosed this decision in its Q2 2026 letter to investors for its Global Growth Strategy Fund. The company stated that although Alcon remains a leader in ophthalmic care, the sluggish performance of the cataract and contact lens markets, coupled with increasing competition in the premium intraocular lens market, prompted it to gradually reduce its holdings and ultimately reallocate capital to higher-growth opportunities such as Schneider Electric.